Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels

American Journal of Pathology

Volumn 171, Issue 4, 2007, Pages 1352-1368

  Kalakonda, Sudhakar ^a   Nallar, Shreeram C ^a   Gong, Ping ^a   Lindner, Daniel J ^c   Goldblum, Simeon E ^a   Reddy, Sekhar P ^b   Kalvakolanu, Dhananjaya V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; MITOGENIC AGENT; PAXILLIN; PLAKOGLOBIN; PROTEIN GRIM 19; PROTEIN SUBUNIT; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; STAT3 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL MIGRATION; CELL MOTILITY; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOMATIC CELL GENETICS; TUMOR GENE;

EID: 35348886003     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.070241     Document Type: Article

References (85)

1. Kalvakolanu DV, Borden EC: Interferons: cellular and molecular biology of their actions. Encyclopedia of Cancer. Edited by JR Bertino. San Diego, Academic Press, 2002, pp 511-521
2. Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848
3. Kalvakolanu DV: The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev 2004, 15:169-194
4. Lindner DJ, Borden EC, Kalvakolanu DV: Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997, 3:931-937
5. Lippman SM, Kalvakolanu DV, Lotan R: Retinoids and interferons in non-melanoma skin cancer. J Investig Dermatol Symp Proc 1996, 1:219-222
6. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF, Taniguchi T: Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993, 259:968-971
7. Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF, Rosenbauer F, Huhn D, Wittig B, Horak I, Neubauer A: Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998, 91:22-29
8. Hao SX, Ren R: Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000, 20:1149-1161
9. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002, 30:181-184
10. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A: DAP kinase links the control of apoptosis to metastasis. Nature 1997, 390:180-184
11. Der SD, Zhou A, Williams BRG, Silverman RH: Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998, 95:15623-15628
12. Hofmann ER, Boyanapalli M, Lindner DJ, Weihua X, Hassel BA, Jagus R, Gutierrez PL, Kalvakolanu DV: Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol 1998, 18:6493-6504
13. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV: Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-β and retinoic acid combination, using a genetic approach. J Biol Chem 2000, 275:33416-33426
14. Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X, Reddy SP, Resnick MB, Kalvakolanu DV: A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006, 25:7138-7147
15. Chidambaram NV, Angell JE, Ling W, Hofmann ER, Kalvakolanu DV: Chromosomal localization of human GRIM-19, a novel IFN-β and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2000, 20:661-665
16. Zhang X, Huang Q, Yang Z, Li Y, Li CY: GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 2004, 64:2474-2481
17. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simoes M: Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005, 92:1892-1898
18. Seo T, Lee D, Shim YS, Angell JE, Chidambaram NV, Kalvakolanu DV, Choe J: Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol 2002, 76:8797-8807
19. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF, Poli V, Stark GR, Kalvakolanu DV: The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003, 100:9342-9347
20. Lufei C, Ma J, Huang G, Zhang T, Novotny-Diermayr V, Ong CT, Cao X: GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003, 22:1325-1335
21. Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954
22. Wang Y, Prywes R: Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene 2000, 19:1379-1385
23. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298
24. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003, 33:401-406
25. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003, 9:493-501
26. Kimura G, Itagaki A, Summers J: Rat cell line 3y1 and its virogenic polyoma- and sv40-transformed derivatives. Int J Cancer 1975, 15:694-706
27. Ushijima T, Makino H, Nakayasu M, Aonuma S, Takeuchi M, Segawa K, Sugimura T, Nagao M: Presence of p53 mutations in 3Y1-B clone 1-6: a rat cell line widely used as a normal immortalized fibroblast. Jpn J Cancer Res 1994, 85:455-458
28. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310
29. Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983, 11:1475-1489
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112
31. Frame MC, Fincham VJ, Carragher NO, Wyke JA: v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002, 3:233-245
32. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269:81-83
33. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998, 18:2553-2558
34. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura EB: Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24:3397-3408
35. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR: Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005, 65:939-947
36. Hunter T, Pines J: Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582
37. Evan G, Littlewood T: A matter of life and cell death. Science 1998, 281:1317-1322
38. 1 progression. Adv Cancer Res 1998, 74:1-24
39. Patel MS, Korotchkina LG: Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp Mol Med 2001, 33:191-197
40. Levy DE, Darnell JE: STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662
41. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M: Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992, 118:703-714
42. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W: Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/β-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993, 120:757-766
43. Hauck CR, Hsia DA, Ilic D, Schlaepfer DD: v-Src SH3-enhanced interaction with focal adhesion kinase at β1 integrin-containing invadopodia promotes cell invasion. J Biol Chem 2002, 277:12487-12490
44. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM, Courtneidge SA: The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem 2003, 278:16844-16851
45. Lin SL, Garber EA, Wang E, Caliguiri LA, Schellekens H, Goldberg AR, Tamm I: Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol 1983, 3:1656-1664
46. Perucho M, Esteban M: Inhibitory effect of interferon on the genetic and oncogenic transformation by viral and cellular genes. J Virol 1985, 54:229-232
47. Seliger B, Kruppa G, Pfizenmaier K: Murine gamma interferon inhibits v-mos-induced fibroblast transformation via down regulation of retroviral gene expression. J Virol 1987, 61:2567-2572
48. Contente S, Kenyon K, Rimoldi D, Friedman RM: Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990, 249:796-798
49. Seliger B, Pfizenmaier K, Schafer R: Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts. J Virol 1991, 65:6307-6311
50. Lallemand C, Kahan A, Telvi L, Joret AM, Gerfaux J: An antisense interferon-β RNA abolishes repression of c-fos gene expression. Oncogene 1992, 7:1109-1118
51. Tanaka N, Ishihara M, Taniguchi T: Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 1994, 83:191-196
52. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001, 98:7319-7324
53. Lukas C, Sorensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM, Bartek J, Lukas J: Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999, 401:815-818
54. Onishi T, Zhang W, Cao X, Hruska K: The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyclin-dependent kinase 1 (cdc2) in osteoblast precursors. J Bone Miner Res 1997, 12:1596-1605
55. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev 2007, 21:1396-1408
56. Saijo K, Schmedt C, Su IH, Karasuyama H, Lowell CA, Reth M, Adachi T, Patke A, Santana A, Tarakhovsky A: Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development. Nat Immunol 2003, 4:274-279
57. Yu Z, Kone BC: The STAT3 DNA-binding domain mediates interaction with NF-κB p65 and inducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol 2004, 15:585-591
58. Courter DL, Lomas L, Scatena M, Giachelli CM: Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-κB. J Biol Chem 2005, 280:12145-12151
59. Bijli KM, Minhajuddin M, Fazal F, O'Reilly MA, Platanias LC, Rahman A: c-Src interacts with and phosphorylates RelA/p65 to promote thrombin-induced ICAM-1 expression in endothelial cells. Am J Physiol 2007, 292:L396-L404
60. Livolsi A, Busuttil V, Imbert V, Abraham RT, Peyron JF: Tyrosine phosphorylation-dependent activation of NF-κB. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases. Eur J Biochem 2001, 268:1508-1515
61. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63-71
62. Zhong Z, Wen Z, Darnell Jr JE: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98
63. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S, Yasukawa K, Heinrich P, Stark GR, Kerr IM: A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 1995, 14:1421-1429
64. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, Kishimoto T, Barbieri G, Pellegrini S, Sendtner M, Heinrich PC, Horn F: Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994, 263:89-92
65. Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, Hamaguchi M: The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene 2000, 19:4795-4801
66. Kalakonda S, Nallar SC, Lindner DJ, Hu J, Reddy SP, Kalvakolanu DV: Tumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res 2007, 67:6212-6220
67. Frame MC: Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004, 117:989-998
68. Wu X, Gan B, Yoo Y, Guan JL: FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev Cell 2005, 9:185-196
69. Zou JX, Liu Y, Pasquale EB, Ruoslahti E: Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity. J Biol Chem 2002, 277:1824-1827
70. Mizutani K, Miki H, He H, Maruta H, Takenawa T: Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer Res 2002, 62:669-674
71. Ozawa M, Ohkubo T: Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. J Cell Sci 2001, 114:503-512
72. Li L, Okura M, Imamoto A: Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion. Mol Cell Biol 2002, 22:1203-1217
73. Takeya T, Hanafusa H: DNA sequence of the viral and cellular src gene of chickens. II. Comparison of the src genes of two strains of avian sarcoma virus and of the cellular homolog. J Virol 1982, 44:12-18
74. Loeb DM, Woolford J, Beemon K: pp60c-src has less affinity for the detergent-insoluble cellular matrix than do pp60v-src and other viral protein-tyrosine kinases. J Virol 1987, 61:2420-2427
75. Hirai H, Varmus HE: Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src. Mol Cell Biol 1990, 10:1307-1318
76. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC: The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286:309-312
77. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H: CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J Biol Chem 1991, 266:24249-24252
78. Imamoto A, Soriano P: Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell 1993, 73:1117-1124
79. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, Okada M, Aizawa S: Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993, 73:1125-1135
80. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ: Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999, 21:187-190
81. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004, 4:891-899
82. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV: c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997, 94:6658-6663
83. Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997, 57:5328-5335
84. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A: Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1α expression under normoxia. J Biol Chem 2002, 277:42919-42925
85. Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE, Hirst J: GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH: ubiquinone oxidoreductase (complex I). J Biol Chem 2001, 276:38345-38348